

PRIVATE FUNDING OPPORTUNITIES: MAR 31, 2017

Please contact Corporate & Foundation Relations in the Office of Development at <u>devcfr@mgh.harvard.edu</u> if you wish to submit a proposal in response to any of these opportunities. Note that proposals are still routed through the standard InfoEd/Research Management process.

Please be aware that any grant that brings in less than <u>15% in indirect costs (IDC)</u> will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submission of the award. <u>Training fellowships</u> from foundations, public charity, and non-profit organizations <u>are excluded</u> from this minimum IDC requirement.

1. Congenital Heart Disease Research Grants, Children's Heart Foundation

The CHF supports clinical and basic science research in congenital heart disease, including, but not limited to the following areas: molecular genetics, biochemistry, pharmacology, devices and procedural research (cardiac catheterization and surgery), and long-term care of adults with congenital birth defects.

Award Amount: \$100,000 paid over 2 years Indirect Costs: None Proposal Deadline: Jun 2, 2017 Website: http://www.childrensheartfoundation.org/for-scientists/call-for-research-proposals

2. Independent Grants for Learning & Change (IGL&C): Request for Improving Health Care Capacity in Immuno-Oncology, Pfizer, Inc.

Pfizer - Independent Grants for Learning & Change (IGLC) and Merck KGaA, Darmstadt, Germany - Global Medical Education (GME) are collaborating to provide grant support for continuing professional education in the area of Immuno-Oncology. Tumor types of current interest to our Immuno-Oncology alliance include Skin Cancer (Merkel Cell Carcinoma), Non-Small Cell Lung Cancer (NSCLC), Head & Neck Cancer, Ovarian Cancer, Gastric Cancer, Renal Cell Carcinoma and Bladder Cancer.

Traditionally, an initiative like implementing evidence-based practice in immuno-oncology to improve the care of cancer patients is pursued through educational programming for physicians. However, the approach of this joint RFP in improving health care capacity suggests that more than traditional educational programming is necessary. The achievement of a goal to



Do you want to learn more about identifying external funding opportunities? See <u>ECOR's website</u> for information on the funding opps database, **COS Pivot** or contact Amy Robb <<u>arobb@mgh.harvard.edu</u>> to schedule an individual consultation or group training session. improve the health of patients is dependent on improving the capabilities of organizations and societies as well as the individual clinicians.

Geographic Region: North America (United States and Canada); European Union (including Switzerland and Israel)

Target Audience: Medical Oncologists and all members of health care team involved in the care of cancer patients. Urologists who may be treating bladder, renal, and prostate cancers are also included.

Award Amount: Up to \$1 million Indirect Costs: 28% LOI Deadline: May 1, 2017 Website: <u>http://www.pfizer.com/responsibility/grants_contributions/request_proposals</u>

3. Independent Grants for Learning & Change (IGLC): Track 2 - Call for Grant Applications (CGA) - Patient Education in Advanced or Metastatic Breast Cancer Treatment (CGA - MBC Patient Education), Pfizer, Inc.

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

Geographic Scope: United States Only

Clinical Area: Advanced or Metastatic Breast Cancer

Specific Area of Interest for this CGA:

It is Pfizer's intent to support patient education programs designed to advance patient understanding of advanced or metastatic breast cancer and improve their ability to make informed decisions about their care.

Educational initiatives may include:

- Disease information including factors that influence treatment decisions (i.e. disease specific, treatment specific)
- Information on current treatment options

- Increasing access to clinical trials, in particular, those with a focus on diversity and inclusion
- Patient and caregiver support programs
- Guides for patients on how to have a meaningful discussion with their physician about their own treatment (e.g. taking into consideration the needs and goals of patients, building the patient's understanding of what is likely to occur, and aligning the expectations of both patients and physicans)

Educational programs should be designed for patients, their caregivers, and their families. Proposals for this CGA should not include healthcare provider training or professional education.

All activity types (e.g. live, print, online, mobile applications) will be considered through this CGA, but we are particularly interested in innovative, technology-enabled solutions that will help patients living with advanced or metastic breast cancer increase their understanding of and participation in their care plan. Efforts should be made to encourage interaction, incorporate case-based discussions, and/or provide opportunities to extend and reinforce learning.

Award Amount: Up to \$250,000 Indirect Costs: 28% LOI Deadline: Apr 21, 2017 Website: <u>http://www.pfizer.com/responsibility/grants_contributions/grants_process</u>

4. 2017 Global ASPIRE Young Investigator Research Awards in Endocrinology, Pfizer, Inc./ Advancing Science through Pfizer - Investigator Research Exchange (ASPIRE Research Awards)

Funding is for basic science, translational or clinical research, in the areas of focus, generating data that will help advance the science of endocrine diseases in adults and children.

As competition for research funding opportunities increases, the ASPIRE program underscores Pfizer's commitment to supporting promising young investigators with an interest in advancing their academic research careers in endocrinology.

The mission of the award is to advance the medical knowledge of the fundamental mechanisms of disease, as well as mechanisms of action of current and potential future treatments, and to improve the care of patients with endocrine disorders.

Scientific research continues to advance our knowledge and understanding of endocrine disorders and their treatments.

The award is designed to:

- Support young investigators working in the field of endocrinology.
- Advance the understanding of disease mechanisms or treatments through translational basic science or clinical research in order to enhance the clinical care of patients with endocrine diseases.

Funding will be provided to research proposals that seek to explore basic, translational, or clinical research in the area of endocrine disease in adults and children:

- Clinical and Translational Research in the GH and IGF-I Axis
- Morbidity and Mortality in Patients with Acromegaly
- Novel Measures of Growth Hormone Treatment Benefits

Award Amount: \$50,000 for 1 year Indirect Costs: Unpublished Application Deadline: Jun 2, 2017 Website: <u>https://www.aspireresearch.org/endocrineus/apply.html</u>

5. Advancing Science Through Pfizer: Investigator Research Exchange (ASPIRE) Gene Therapy for Hemophilia Research Awards Program, Pfizer, Inc./Advancing Science through Pfizer - Investigator Research Exchange (ASPIRE Research Awards)

The 2017 ASPIRE Gene Therapy in Hemophilia Research Awards Program is a competitive grants program that reflects the commitment of Pfizer Hemophilia Rare Disease group to support ongoing basic science and clinical investigation in gene therapy for hemophilia.

Ongoing basic science research and clinical research are critical to deepen understanding of disease mechanisms and to ensure advancement of management strategies for hemophilia and related comorbidities. In an era of increased competition for research funding, the 2017 ASPIRE Gene Therapy in Hemophilia Research Awards Program is designed to support laboratory and clinical research in pathogenesis, complications, management, and clinical outcomes of gene therapy for hemophilia.

Mission

To support research through a competitive grants program that advances medical knowledge in the area of Gene Therapy for Hemophilia. The 2017 program will focus on Hemophilia B.

Areas of Research Focus

- 1. Patients with Mild Hemophilia B
 - Natural history of disease
 - Arthropathy: presence, development, clinical burden & Joint damage
 - Quality of Life/Work analysis
 - Clinical profile & healthcare utilization
 - Comorbidities: prevalence, severity, management

- Cost of Care, including non-hemophilia related healthcare utilization
- 2. Basic science of Adeno-associated virus 8 (AAV8)
 - Basic science, tropism, transduction efficiency & tolerability
 - AAV antibody titer assessment, reduction, tolerance
 - Role of immunosuppression in managing transaminitis & expression levels

Applicants/Investigators are expected to:

- Design studies and generate data to address at least one of the Research Areas of interest
- Provide a Publication Plan describing submission of abstracts to (a) congress(es) or submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines.
- Complete the study within 24-30 months from the time that the grant is awarded

No other government, non-governmental, or industry-sponsored projects may cover the same scope of work as the grant application to the ASPIRE Research Awards Program. However, an ASPIRE Research Award may be related to other funding from foundations or government agencies, as long as there is no direct overlap. In the application, it is the responsibility of the applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.

Once awarded, an ASPIRE Research Award cannot be amended upwards with additional funding support from Pfizer (via the standard Investigator Initiated Research [IIR] process or separate competitive grant program), nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the External Review Committee be provided. If supplemental funding is required, it must be secured from sources outside of Pfizer. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer-supported competitive grant program.

ASPIRE Research Awards cannot be provided to studies that are already in progress.

Award Amount: Up to \$250,000 paid over 1-2 years Indirect Costs: 28%

6. New Connections: Increasing Diversity of RWJF Programming, Robert Wood Johnson Foundation (RWJF)

New Connections: Increasing Diversity of RWJF Programming is celebrating its 11th year; over the history of the program, it has supported research grants and career development opportunities for a network of more than 920 researchers from diverse, underrepresented and historically disadvantaged backgrounds. New Connections is a career development program for early career researchers, providing support to grantees and other individuals who are part of a network of eligible researchers. Through grantmaking, mentorship, career development and networking, New Connections enhances the research capacity of its grantees and network members. The researchers in this program come from multiple disciplines (health, social sciences, business, urban planning, architecture and engineering); work to build the case for a Culture of Health with strong qualitative and quantitative research skills; and produce and translate timely research results.

7. Learning Partnerships, Grace and Harold Sewell Memorial Fund

The purpose of the Partnerships is to place experienced librarians and information professionals within leading health care or research organizations in order for both partners to gain a better understanding of how best information sciences can be effectively applied in each environment. The Fund believes that this experience will facilitate a bridging of cultures resulting in a more creative and effective application of information science in the health care arena.

The program has been designed to provide funding for a medical or health care librarian or information scientist to spend approximately a year in the environment of a host organization. Host organizations will present a learning environment, a series of activities, and access to organizational leaders which will allow the librarian or information scientist to more fully understand the nature of the organization's work, its decision-making processes, the clients served and the health care issues addressed. The selected applicants will participate in team settings designed to utilize the librarian's skills and knowledge in non-traditional ways. Immersion is the goal and expanded knowledge the anticipated result for both partners.

As they come to identify with the host clients in a work setting, librarians will broaden their perceptions and deepen their understanding of the clients' goals, thinking, knowledge base and methodology. Client hosts will receive assistance from a skilled librarian capable of helping in both non-traditional and traditional library activities. The host will also gain insight into information management techniques and librarian capabilities. The partnership will also inform the librarian partner about health sciences topics and current research methodology or practice protocols. Both partners will learn how their skills and knowledge can be more effectively integrated to increase the quality of research or health care.

To apply for consideration as a Host Organization, applicants must meet the following criteria:

- Have a project and a team of employees responsible for outcomes that would benefit from the wide range of skills of an experienced mid-career health sciences librarian or information scientist (the Sewell Fund Fellow).
- An environment which would allow the Fellow to be immersed in the organization's work, learn from leaders more about the health sciences issues of importance to your

organization, and allow the Fellow to contribute in a substantive way to the success of the organization.

Award Amount: \$70,000 Indirect Costs: None Application Deadline: Apr 15, 2017 Website: <u>http://www.sewellfund.org/learning-partnerships.html</u>